Back to Search

A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors

  • Protocol Number: 202505061
  • Principal Investigator: Weiss, Mia
  • Cancer Types: Early Phase

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).

Protocol Interventions

Biological: XB628